Table 3.

Study 20120265 VEGF-related AEs

AEABP215 (n = 324)EU-approved bevacizumab (n = 309)
All gradesGrades 3–4All gradesGrades 3–4
Hypertension19%7%16%6%
Hemorrhages22%2%21%1%
Venous thromboembolism4%2%5%3%
Arterial thromboembolism2%1%a1%1%
Proteinuria8%<1%6%<1%
Gastrointestinal perforation1%1%1%1%
  • aTwo additional fatal events (grade 5).